<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966288</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0616</org_study_id>
    <nct_id>NCT02966288</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs</brief_title>
  <official_title>A Randomized Controlled Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <brief_summary>
    <textblock>
      The study objective is to determine whether a single intra-articular dose of an
      anti-inflammatory (Toradol) will reduce the need for other analgesic medications and, if so,
      how long the benefits will last.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Medication Usage for Breakthrough Pain</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Level as Assessed by a Visual Analogue Scale</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Medication Usage for Breakthrough Pain</measure>
    <time_frame>1 week post treatment</time_frame>
    <description>The number of pills will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication Usage for Breakthrough Pain</measure>
    <time_frame>2 weeks post treatment</time_frame>
    <description>The number of pills will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication Usage for Breakthrough Pain</measure>
    <time_frame>3 weeks post treatment</time_frame>
    <description>The number of pills will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication Usage for Breakthrough Pain</measure>
    <time_frame>4 weeks post treatment</time_frame>
    <description>The number of pills will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Level as Assessed by a Visual Analogue Scale</measure>
    <time_frame>1 week post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Level as Assessed by a Visual Analogue Scale</measure>
    <time_frame>2 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Level as Assessed by a Visual Analogue Scale</measure>
    <time_frame>3 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Level as Assessed by a Visual Analogue Scale</measure>
    <time_frame>4 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who had a second visit to a Emergency Department or Clinic</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthritic Knee Pain</condition>
  <arm_group>
    <arm_group_label>Toradol injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toradol</intervention_name>
    <description>3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.</description>
    <arm_group_label>Toradol injection</arm_group_label>
    <other_name>ketorolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral NSAID</intervention_name>
    <description>800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))</description>
    <arm_group_label>Oral NSAID</arm_group_label>
    <other_name>ibuprofen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with radiographic evidence of osteoarthritis (OA) who present to the ED with
             a chief complaint of knee pain that the treating provider attributes to their
             arthritis.

        Exclusion Criteria:

          -  Acute knee trauma

          -  Intra-articular steroid injection within 6 months

          -  History of gout or rheumatoid arthritis

          -  X ray evidence of pathologic fracture, malignancy, or other non-OA cause of symptoms

          -  Signs or symptoms or high risk of acute infection: Recent fevers and chills; Erythema,
             warmth, or pain out of proportion to exam; History of hemodialysis; History of IV drug
             use

          -  Lidocaine allergy

          -  Any contraindication to NSAID therapy, including: Allergy; Pregnancy; History of renal
             insufficiency; History of gastritis, GERD or GI bleeding; Primary care physician's
             restriction of its use

          -  Contraindication to the procedure, including: Hemophilia; History of total knee
             replacement of the affected joint

          -  An inability to give informed consent; Active psychosis; Diminished capacity requiring
             another person to provide consent for medical treatment

          -  An inability to be contacted for follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly A Chambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Kimberly A Chambers</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

